The stock is too cheap for LT holders. The sell side and market is going to realize this that there likely to hit all their endpoints with schizophrenia as PDP and schizophrenia trials are really similar. ADP, who knows.
The trials show that it works really well when combined with all the top-companies APs (JNJ, AZN, AGN, etc). And it reduces the nasty effects of them, making their APs safer aka better product and forces nearby competition to also use. It is both a complement and a competitor to the $25 billion antipsychotic market.
This is not some Shkreli orphan medicine that you give 1-2x a patient and their cured for the rest of their life. This is a replenishing medicine that needs to be taken on a daily basis. There going to pile up cashflows from quick revenue growth and the end market is huge. International pdp and us/int schizophrenia as well.
Nursing homes will see this as a blessing when dealing with PDP patients bam give them nuplazid.
Schizophrenic person coming in to a hospital? Bam give them nuplazid. Hallucinating drug user in ER? Bam give them nuplazid. Its solving a lot of problems.
They will have 100% market share in a $3B PDP US market, 100% market share in a $3B PDP International market, and 100% market share in a $8B schizophrenia US&Interantional market. I'm obviously a bull, so this is just my opinion, invest at your own peril as it is a volatile stock.